Kronos Bio LLC

Kronos Bio LLC Net Debt/FCF

Delisted

The Net Debt to Free Cash Flow Ratio of Kronos Bio LLC (KRON) as of Nov 2, 2026 is 1.72. In the previous year, Net Debt to Free Cash Flow Ratio was 2.18 — a change of -21.29% (lower).

Net Debt/FCF

1.72

YoY

-21.29%

Last updated:

Net Debt to Free Cash Flow Ratio of Kronos Bio LLC is 2024 1.72 . Net Debt to Free Cash Flow Ratio of Kronos Bio LLC was 2023 2.18 . It decreases by -21.29% lower compared to the previous year.

The Kronos Bio LLC Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
1.35 USD
Jan 1, 2019
5.11 USD
Jan 1, 2020
9.73 USD
Jan 1, 2021
2.78 USD
Jan 1, 2022
2.71 USD
Jan 1, 2023
2.18 USD
Jan 1, 2024
1.72 USD
The Kronos Bio LLC Net Debt/FCF history
YEARNet Debt/FCFYoY
1.72-21.29%
2.18-19.45%
2.71-2.48%
2.78-71.45%
9.73+90.34%
5.11+279.50%
1.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kronos Bio LLC Stock analysis

What does Kronos Bio LLC do? Kronos Bio Inc is a biotech company founded in 2017 by an experienced team, specialized in developing new therapeutics for cancer treatment. The company is based in Cambridge, Massachusetts and collaborates closely with leading scientific institutions. Kronos Bio Inc's business model focuses on identifying and researching new targets to develop drugs for the treatment of cancer and other diseases. The company utilizes artificial intelligence and machine learning to identify molecular mechanisms, enabling better prediction of the effectiveness of new drugs. Kronos Bio Inc is divided into different divisions, each focusing on specific therapeutic approaches. The "Transcription Regulation" division explores the control of gene expression in tumor cells and seeks potential points of intervention. The "Epigenetics" division, on the other hand, investigates how cells modify their DNA and the role this plays in the development of cancer. Another division focuses on blocking specific enzyme activities that are considered essential factors for the growth of tumor cells. Currently, Kronos Bio Inc does not offer concrete products as it is still in the development phase. However, the company has already established a number of collaborations with other companies and scientific institutions to research and further develop new drug candidates. One of the most significant partnerships is with the pharmaceutical company Gilead Sciences, which has the option to license selected drug candidates from Kronos Bio Inc as part of the collaboration. Overall, Kronos Bio has quickly made a name for itself in the biotech industry with its innovative approach and ambitious plans to develop new drugs against cancer. The company has raised several million dollars in capital and has prominent investors such as Omega Funds and Vida Ventures on board. The goal of Kronos Bio is to develop new therapies that allow for improved survival rates and a higher quality of life for cancer patients. Kronos Bio LLC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kronos Bio LLC stock

Net Debt to Free Cash Flow Ratio of Kronos Bio LLC is 1.72 in 2024.

Net Debt to Free Cash Flow Ratio of Kronos Bio LLC changed from 2.18 to 1.72, representing a -21.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Kronos Bio LLC since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Kronos Bio LLC with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Kronos Bio LLC

All Key Metrics — Kronos Bio LLC